BriaCell Therapeutics (NASDAQ:BCTX) Earns "Buy" Rating from

HC Wainwright reiterated their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX – Free Report) in a report published on Friday, Benzinga reports. They currently have a $18.00 price objective on the stock. BriaCell Therapeutics Stock Performance Shares of BCTX opened at $1.44 on Friday. The stock has a fifty day moving average price of […]

Related Keywords

Canada , , Briacell Therapeutics Corp , Principal Fund , National Bank , Wealth Group , J Harrison Partners Inc , Kj Harrison Partners Inc , Briacell Therapeutics , Free Report , Cell Therapeutics , Get Free Report , Bridge Wealth Group , Partners Inc , Briacell Therapeutics Daily ,